`
` __________________________________________________________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`
`FRESENIUS KABI USA, INC. and FRESENIUS KABI SWISSBIOSIM
`GmbH
`Petitioner,
`
`
`v.
`
`
`AMGEN, INC. and AMGEN MANUFACTURING LIMITED
`Patent Owner.
`
`
`IPR2019-00971
`
`Patent No. 9,856,287 B1
`
`Title: REFOLDING PROTEINS USING A CHEMICALLY CONTROLLED
`REDOX STATE
`
`
`
`PETITIONERS’ UPDATED MANDATORY NOTICES
`
`Mail Stop PATENT BOARD
`Patent Trial and Appeal Board
`United States Patent and Trademark Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`
`
`
`
`Petitioners hereby submit the following updated mandatory notices in
`
`connection with the above captioned inter partes review of U.S. Patent No.
`
`9,856,287 to update the disclosure of related matters. Specifically, Petitioners
`
`submit these updated mandatory notices to inform the Board that the ’287 patent is
`
`no longer at issue in any litigations or other proceedings before the Board.
`
`A. Real Party-In-Interest (§ 42.8(b)(1)) (No Change)
` The real parties in interest are Fresenius Kabi USA, LLC, Fresenius Kabi
`
`SwissBioSim GmbH, Fresenius Kabi AG, Fresenius Kabi Pharmaceuticals
`
`Holding, Inc., Fresenius Kabi Deutschland GmbH, Fresenius SE & Co. KGaA, Dr.
`
`Reddy’s Laboratories, Ltd., Dr. Reddy’s Laboratories, S.A., and Dr. Reddy
`
`Laboratories Inc.
`
`B. Related Matters (§ 42.8(b)(2)) (Updated)
`The ’287 Patent was the subject of the following litigations and post-grant
`
`proceedings: Amgen Inc. et al. v. Adello Biologics LLC, 2:18-cv-03347 D.N.J.;
`
`Amgen Inc. et al. v. Apotex Inc. et al., 19-cv-61828, S.D. Fla; and Adello Biologics,
`
`LLC. et al. v. Amgen Inc., PGR-2019-00001 (P.T.A.B.).
`
`On November 14, 2019, the parties stipulated and agreed to a dismissal of all
`
`remaining claims and counterclaims in Amgen Inc. et al. v. Apotex Inc. et al., 19-
`
`cv-61828, S.D. Fla. On November 25, 2019, the parties stipulated and agreed to a
`
`dismissal of all remaining claims and counterclaims in the Amgen Inc. et al. v.
`
`
`
`Adello Biologics LLC, 2:18-cv-03347 D.N.J. On December 3, 2019, the parties
`
`filed joint motions to terminate the Adello Biologics, LLC. et al. v. Amgen Inc.,
`
`PGR-2019-00001 (P.T.A.B.).
`
`In addition, U.S. Patent Application No. 15/889,559 is pending and claims
`
`priority to the ’287 Patent.
`
`C. Identification of Counsel (§ 42.8(b)(3)) and Service Information
`(§ 42.8(b)(4)) (No Change)
`Lead Counsel
`Back-Up Counsel
`Robert V. Cerwinski
`Huiya Wu
`(to seek pro hac vice
`(Reg. No. 44,411)
`admission)
`Goodwin Procter LLP,
`Goodwin Procter LLP,
`620 Eighth Avenue,
`620 Eighth Avenue,
`New York, NY 10018,
`New York, NY 10018,
`T: (212) 813-7295
`T: (212) 813-8800
`Fax: (212) 355-3333
`Fax: (212) 355-3333
`hwu@goodwinlaw.com
`rcerwinski@goodwinlaw.com
`
`Back-Up Counsel
`Linnea Cipriano
`(Reg. No. 67,729)
`Goodwin Procter LLP,
`620 Eighth Avenue,
`New York, NY 10018,
`T: (212) 813-7295
`Fax: (212) 355-3333
`lcipriano@goodwinlaw.com
`
`
`
`D. Electronic Service (No Change)
`Please direct all correspondence to lead counsel and back-up counsel at the
`
`contact information above. Petitioners consent to electronic mail service at the
`
`following addresses: hwu@goodwinlaw.com; rcerwinski@goodwinlaw.com;
`
`lcipriano@goodwinlaw.com.
`
`Date: December 4, 2019
`
`
`
`
`
`
`
`
`
`Respectfully Submitted,
`
`By: /s/ Huiya Wu
`Huiya Wu (Reg. No. 44,411)
`Robert V. Cerwinski (to seek pro hac vice
`admission)
`
`
`
`Linnea Cipriano (Reg. No. 67,729)
`GOODWIN PROCTER LLP
`The New York Times Building
`620 Eighth Avenue
`New York, NY 10018
`(212) 813-8800 (telephone)
`(212) 355-3333 (facsimile)
`hwu@goodwinlaw.com
`rcerwinski@goodwinlaw.com
`lcipriano@goodwinlaw.com
`
`Counsel for Petitioners
`
`
`
`
`
`
`
`
`
`CERTIFICATE OF SERVICE
`
`The undersigned hereby certifies that, on December 4, 2019, a copy of the
`
`foregoing PETITIONERS’ UPDATED MANDATORY NOTICES was served on
`
`the counsel of record for the Patent Owner by filing the same through the PTAB
`
`E2E System as well as delivering a copy via electronic mail to the following
`
`addresses:
`
`
`
`Lead Counsel
`J. Steven Baughman (Reg. No. 47,414)
`PAUL, WEISS, RIFKIND, WHARTON & GARRISON LLP
`2001 K St. NW
`Washington, DC 20006
`Tel: (202) 223-7300
`Fax: (202) 403-3740
`sbaughman@paulweiss.com
`
`Backup Counsel
`Megan Raymond (Reg. No. 72,997)
`PAUL, WEISS, RIFKIND, WHARTON & GARRISON LLP
`2001 K St. NW
`Washington, DC 20006
`Tel: (202) 223-7300
`Fax: (202) 403-3777
`mraymond@paulweiss.com
`
`Date: December 4, 2019
`
`
`
`
`
`
`
`
`
`
`
`Respectfully Submitted,
`By: /s/ Huiya Wu
`Huiya Wu (Reg. No. 44,411)
`
`